Home > Mini Cooper > Clonazepam sale

Clonazepam sale

New products introduced earlier in 1996 boosted our first-quarter sales above the 1995 first-quarter level – particularly our diclofenac sodium tablets for arthritis, said Moldin. In the proposal, Faulding offered to acquire all of the outstanding shares of common stock of the company not currently owned by Faulding Holdings Inc. The company’s leading product by sales in the 4th quarter, and second leading product by sales in the fiscal year, was clonazepam tablets, the generic version of Klonopin(R), an anti-convulsant drug. Faulding with respect to the proposal are ongoing at this time. Faulding’s startup injectable and device business acquired in early 1996 continued to develop their clonazepam sale respective injectable drug and medical device product lines, and as stated above, three of their injectable products were approved by the FDA in the third quarter. The company’s shares are traded on NASDAQ under the symbol FAUL. Teva expects to commence shipment of this product shortly. Clonazepam is a generic equivalent of Roche’s Klonopin, indicated for the treatment of seizure disorders. The shares of Faulding are traded on NASDAQ clonazepam sale under the symbol FAUL. Note: Klonopin(R) is a registered trademark of Roche Laboratories. ELIZABETH, N. –(BUSINESS WIRE)–April 30, 1997–Initial sales of Etodolac and Clonazepam tablets in oral drug business drive fiscal 1997 third quarter sales to $25. 2 million versus $18. 5 million in 1996 third quarter Faulding Inc. After preferred dividends, earnings per clonazepam sale share of common stock were $0. 14 for fiscal 1997 compared with a restated loss of $0. 49 in the prior year. After preferred dividends, income attributable to common stock was a loss of ($0. 03) per share clonazepam sale in the current nine month period compared with a restated loss of ($0. 49) in the prior year’s comparable Clonazepam sale period. Over 60 percent of its sales are generated outside of Israel. CONTACT: Dan Clonazepam sale suesskindchief Financial Officer(011) 972-2-892-811orInvestor Relations:Donna N. The Special Committee has retained the law firm of White & Case to act as its independent legal counsel clonazepam sale and Oppenheimer & Co. Develops, manufactures and markets human pharmaceuticals and medical devices. The company is highly focused on the development of new ANDA and device submissions to the FDA, and continues Clonazepam sale to work towards achieving its goal of 10 new ANDAs per year in the oral business and 5-10 new ANDA and device submissions in the injectable and device businesses. Limited, of its 834,188 shares of Class A Preferred Stock into 5,005,128 shares of Faulding Inc. This quarter’s success was a direct result of the commercial launch of two new oral products that were cleared for marketing less than a year after our initial submission to the FDA. Develops, manufactures and markets human pharmaceuticals and medical devices. Stated the the firm’s profitability and sales volume for the quarter were largely driven by late 3rd quarter product launches of clonazepam tablets and etodolac tablets, and continued strong sales of diclofenac Clonazepam sale tablets, which was launched in March 1996.